Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2021 | Addressing unmet needs in MS: progressive disease and damage repair

Amit Bar-Or, MD, FRCPC, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discusses the current treatment options in multiple sclerosis (MS), as well as the greatest unmet needs facing the field and areas of significant research focus for the near future. The MS treatment landscape has markedly evolved over the last few years, with many more effective therapies available. Early administration of disease modifying therapies has allowed successful prevention of relapses, but targeting progressive disease biology and repairing established damage has proved more difficult. Dr Bar-Or shares some of the approaches currently under investigation to address these unmet needs. This interview took place during the ACTRIMS Forum 2021.

Disclosures

Dr. Bar-Or has participated as a speaker in meetings sponsored by and received consulting fees and/or grant support from: Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme.
Dr. Bar-Or receives research funding from the National Institutes of Health (NIH), The National MS Society (NMSS), the Juvenile Diabetes Research Foundation (JDRF), the Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation and Melissa and Paul Anderson Chair in Neuroinflammation.
Dr. Bar-Or serves on the: Board of Directors for Americas Committee in Treatment and Research in Multiple Sclerosis (ACTRIMS); Education Committee for the Federation of Clinical Immunology Societies (FOCIS); Steering Committee of the Immune Tolerance Network (ITN); President, International Society for Neuroimmunology (ISNI).